VISTIDE
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VISTIDE (cidofovir) is an intravenous nucleotide analog antiviral approved in 1996 for treating cytomegalovirus (CMV) retinitis in immunocompromised patients, particularly those with HIV/AIDS. The drug works by inhibiting viral DNA polymerase and is administered as an IV solution requiring careful dosing and hydration protocols.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; brand team likely focused on retention and managed decline rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VISTIDE offers exposure to specialty antiretroviral and specialty IV drug commercialization in a declining/stable market; career growth is limited by the product's lifecycle stage and shrinking patient population. Ideal for professionals developing expertise in managed decline, reimbursement strategy, and specialty distribution.
Brand ManagerField Sales
Worked on VISTIDE at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.